Core Viewpoint - Ascentage Pharma Group International will release its unaudited interim results for the first half of 2025 and provide business updates on August 20, 2025, with investor webcasts scheduled in both Chinese and English [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancer through the discovery, development, and commercialization of novel therapies [4] - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [4] Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations and is included in China's National Reimbursement Drug List [5] - Olverembatinib is currently undergoing registrational Phase III trials for CML and other related conditions [5] - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and has received approval for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [6] - Lisaftoclax is involved in multiple global registrational Phase III trials targeting different patient groups [6] Research and Development - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, enhancing its research capabilities [7]
Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025